Blog

Preclinical

Maximizing Reproducibility in Cancer Research

November 14, 2019
Read Now
 
TD2 Blog TD2 Blog
Preclinical

Maximizing Reproducibility in Cancer Research

November 14, 2019
Maximizing Reproducibility in Cancer Research Read
Preclinical

Will Your Cancer Drug Move Past Phase 1?

April 18, 2019
Will Your Cancer Drug Move Past Phase 1? Read
Preclinical

The Missing Step Between Phase I and Phase II

January 28, 2019
The Missing Step Between Phase I and Phase II Read
Preclinical

Now Available: Liver Fibrosis Models Fed Choline-Deficient, High-Fat Diets

November 26, 2018
Now Available: Liver Fibrosis Models Fed Choline-Deficient, High-Fat Diets Read
Preclinical

The Keto Diet and Cancer Research: New Insights Emerge

November 7, 2018
The Keto Diet and Cancer Research: New Insights Emerge Read
Bioanalytical

Early DMPK Analysis Means Opportunity for Better Results

October 25, 2018
Early DMPK Analysis Means Opportunity for Better Results Read
Preclinical

In Vitro vs. In Vivo Preclinical Drug Testing

October 1, 2018
In Vitro vs. In Vivo Preclinical Drug Testing Read
Regulatory

Oncology Drug Approval Process

September 18, 2018
Oncology Drug Approval Process Read
Preclinical

Future Trends for Oncology Drug Development

August 30, 2018
Future Trends for Oncology Drug Development Read
Clinical

The Top 5 Challenges in Oncology Drug Development

August 20, 2018
The Top 5 Challenges in Oncology Drug Development Read
Clinical

The Quick-Start Guide to Clinical Strategy

June 5, 2018
The Quick-Start Guide to Clinical Strategy Read
Clinical

Move your research forward, smarter with TD2

June 5, 2018
Move your research forward, smarter with TD2 Read
Preclinical

Research Review: 4 Secrets for Preclinical Success

April 25, 2018
Research Review: 4 Secrets for Preclinical Success Read
Regulatory

What is the Difference Between Research and Commercial IND Categories?

October 1, 2017
What is the Difference Between Research and Commercial IND Categories? Read
Recent Resources
Get free tips, tools and resources by subscribing to the TD2 Newsletter: